We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ipsen SA | EU:IPN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 0.88% | 115.10 | 115.00 | 116.50 | 116.40 | 114.40 | 115.30 | 55,682 | 16:40:00 |
From May 2023 to May 2024
By Adria Calatayud
Shares in Ipsen rose Thursday after the company said a U.S. Food and Drug Administration advisory committee voted in favor of palovarotene as a treatment for ultra-rare bone disease fibrodysplasia ossificans progressiva.
At 0737 GMT, shares in the French pharmaceutical company rose 3.4% at EUR109.80, having earlier risen as much as 6%.
Ipsen said then FDA panel voted 10-4 in favor of the drug as an effective treatment, and 11-3 in favor of considering that the drug's benefits outweigh its risks.
The FDA is currently reviewing a new-drug application for palovarotene and a decision is anticipated by Aug. 16, Ipsen said.
RBC analysts Alistair Campbell and Charles Weston said it now seems likely that the FDA will approve palovarotene in the U.S.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
June 29, 2023 03:56 ET (07:56 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Ipsen Chart |
1 Month Ipsen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
